These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
531 related articles for article (PubMed ID: 28595862)
1. Safety and Efficacy of Uninterrupted Apixaban Therapy Versus Warfarin During Atrial Fibrillation Ablation. Shah RR; Pillai A; Schafer P; Meggo D; McElderry T; Plumb V; Yamada T; Kumar V; Doppalapudi H; Gunter A; Pentecost E; Maddox WR Am J Cardiol; 2017 Aug; 120(3):404-407. PubMed ID: 28595862 [TBL] [Abstract][Full Text] [Related]
2. Feasibility and safety of uninterrupted periprocedural apixaban administration in patients undergoing radiofrequency catheter ablation for atrial fibrillation: Results from a multicenter study. Di Biase L; Lakkireddy D; Trivedi C; Deneke T; Martinek M; Mohanty S; Mohanty P; Prakash S; Bai R; Reddy M; Gianni C; Horton R; Bailey S; Sigmund E; Derndorfer M; Schade A; Mueller P; Szoelloes A; Sanchez J; Al-Ahmad A; Hranitzky P; Gallinghouse GJ; Hongo RH; Beheiry S; Pürerfellner H; Burkhardt JD; Natale A Heart Rhythm; 2015 Jun; 12(6):1162-8. PubMed ID: 25728754 [TBL] [Abstract][Full Text] [Related]
3. A Prospective Randomized Trial of Apixaban Dosing During Atrial Fibrillation Ablation: The AEIOU Trial. Reynolds MR; Allison JS; Natale A; Weisberg IL; Ellenbogen KA; Richards M; Hsieh WH; Sutherland J; Cannon CP JACC Clin Electrophysiol; 2018 May; 4(5):580-588. PubMed ID: 29798783 [TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of apixaban in the patients undergoing the ablation of atrial fibrillation. Nagao T; Inden Y; Shimano M; Fujita M; Yanagisawa S; Kato H; Ishikawa S; Miyoshi A; Okumura S; Ohguchi S; Yamamoto T; Yoshida N; Hirai M; Murohara T Pacing Clin Electrophysiol; 2015 Feb; 38(2):155-63. PubMed ID: 25487164 [TBL] [Abstract][Full Text] [Related]
5. Apixaban versus Warfarin for the Prevention of Periprocedural Cerebral Thromboembolism in Atrial Fibrillation Ablation: Multicenter Prospective Randomized Study. Kuwahara T; Abe M; Yamaki M; Fujieda H; Abe Y; Hashimoto K; Ishiba M; Sakai H; Hishikari K; Takigawa M; Okubo K; Takagi K; Tanaka Y; Nakajima J; Takahashi A J Cardiovasc Electrophysiol; 2016 May; 27(5):549-54. PubMed ID: 26766541 [TBL] [Abstract][Full Text] [Related]
6. Rationale and design of AXAFA-AFNET 5: an investigator-initiated, randomized, open, blinded outcome assessment, multi-centre trial to comparing continuous apixaban to vitamin K antagonists in patients undergoing atrial fibrillation catheter ablation. Di Biase L; Callans D; Hæusler KG; Hindricks G; Al-Khalidi H; Mont L; Cosedis Nielsen J; Piccini JP; Schotten U; Kirchhof P Europace; 2017 Jan; 19(1):132-138. PubMed ID: 28130378 [TBL] [Abstract][Full Text] [Related]
7. Meta-Analysis of Efficacy and Safety of New Oral Anticoagulants Compared With Uninterrupted Vitamin K Antagonists in Patients Undergoing Catheter Ablation for Atrial Fibrillation. Wu S; Yang YM; Zhu J; Wan HB; Wang J; Zhang H; Shao XH Am J Cardiol; 2016 Mar; 117(6):926-34. PubMed ID: 26803384 [TBL] [Abstract][Full Text] [Related]
9. Effect of pre-procedural interrupted apixaban on heparin anticoagulation during catheter ablation for atrial fibrillation: a prospective observational study. Bin Abdulhak AA; Kennedy KF; Gupta S; Giocondo M; Ramza B; Wimmer AP J Interv Card Electrophysiol; 2015 Nov; 44(2):91-6. PubMed ID: 26292959 [TBL] [Abstract][Full Text] [Related]
10. Evaluation of safety and efficacy of periprocedural use of rivaroxaban and apixaban in catheter ablation for atrial fibrillation. Yoshimura A; Iriki Y; Ichiki H; Oketani N; Okui H; Maenosono R; Namino F; Miyata M; Ohishi M J Cardiol; 2017 Jan; 69(1):228-235. PubMed ID: 27131792 [TBL] [Abstract][Full Text] [Related]
11. Comparison of safety of left atrial catheter ablation procedures for atrial arrhythmias under continuous anticoagulation with apixaban versus phenprocoumon. Kaess BM; Ammar S; Reents T; Dillier R; Lennerz C; Semmler V; Grebmer C; Bourier F; Buiatti A; Kolb C; Deisenhofer I; Hessling G Am J Cardiol; 2015 Jan; 115(1):47-51. PubMed ID: 25456870 [TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of efficacy and safety of apixaban and uninterrupted apixaban therapy compared to vitamin K antagonists in patients undergoing catheter ablation for atrial fibrillation. Ukaigwe A; Shrestha P; Karmacharya P; Hussain SK; Samii S; Gonzalez MD; Wolbrette D; Naccarrelli GV J Interv Card Electrophysiol; 2017 Mar; 48(2):223-233. PubMed ID: 27771820 [TBL] [Abstract][Full Text] [Related]
13. Apixaban for periprocedural anticoagulation during catheter ablation of atrial fibrillation: a systematic review and meta-analysis of 1691 patients. Blandino A; Bianchi F; Biondi-Zoccai G; Grossi S; Conte MR; Rametta F; Gaita F J Interv Card Electrophysiol; 2016 Sep; 46(3):225-36. PubMed ID: 27217030 [TBL] [Abstract][Full Text] [Related]
14. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685 [TBL] [Abstract][Full Text] [Related]
15. When is it appropriate to stop non-vitamin K antagonist oral anticoagulants before catheter ablation of atrial fibrillation? A multicentre prospective randomized study. Yu HT; Shim J; Park J; Kim TH; Uhm JS; Kim JY; Joung B; Lee MH; Kim YH; Pak HN Eur Heart J; 2019 May; 40(19):1531-1537. PubMed ID: 30590600 [TBL] [Abstract][Full Text] [Related]
16. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban. Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583 [TBL] [Abstract][Full Text] [Related]
17. Renal function and risk of stroke and bleeding in patients undergoing catheter ablation for atrial fibrillation: Comparison between uninterrupted direct oral anticoagulants and warfarin administration. Yanagisawa S; Inden Y; Fujii A; Ando M; Funabiki J; Murase Y; Takenaka M; Otake N; Ikai Y; Sakamoto Y; Shibata R; Murohara T Heart Rhythm; 2018 Mar; 15(3):348-354. PubMed ID: 29107192 [TBL] [Abstract][Full Text] [Related]
18. Amiodarone, anticoagulation, and clinical events in patients with atrial fibrillation: insights from the ARISTOTLE trial. Flaker G; Lopes RD; Hylek E; Wojdyla DM; Thomas L; Al-Khatib SM; Sullivan RM; Hohnloser SH; Garcia D; Hanna M; Amerena J; Harjola VP; Dorian P; Avezum A; Keltai M; Wallentin L; Granger CB; J Am Coll Cardiol; 2014 Oct; 64(15):1541-50. PubMed ID: 25301455 [TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes and management associated with major bleeding in patients with atrial fibrillation treated with apixaban or warfarin: insights from the ARISTOTLE trial. Held C; Hylek EM; Alexander JH; Hanna M; Lopes RD; Wojdyla DM; Thomas L; Al-Khalidi H; Alings M; Xavier D; Ansell J; Goto S; Ruzyllo W; Rosenqvist M; Verheugt FW; Zhu J; Granger CB; Wallentin L Eur Heart J; 2015 May; 36(20):1264-72. PubMed ID: 25499871 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]